THRD

5.26

1.68% -0.09

Dopo l'orario di chiusura: 5.23 -0.03 -0.57%

Third Harmonic Bio Inc (THRD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$5.35

Aprire:

$5.38

Volume 24 ore:

141.89K

Relative Volume:

0.58

Capitalizzazione di mercato:

$237.01M

Reddito:

Utile/perdita netta:

$-32.74M

Rapporto P/E:

-6.4146

EPS:

-0.82

Flusso di cassa netto:

$-24.89M

1 W Prestazione:

-2.95%

1M Prestazione:

-48.88%

6M Prestazione:

-56.67%

1 anno Prestazione:

-39.33%

Intervallo 1D:

$5.25

$5.56

Intervallo di 1 settimana:

$5.07

$5.69

Portata 52W:

$5.07

$16.94

Third Harmonic Bio Inc Stock (THRD) Company Profile

Nome

Third Harmonic Bio Inc

Settore

Healthcare (1173)

Industria

Biotechnology (678)

Telefono

(209) 727-2457

Indirizzo

1700 MONTGOMERY STREET, SAN FRANCISCO

Dipendente

Cinguettio

Prossima data di guadagno

Ultimi documenti SEC

THRD's Discussions on Twitter

Confronta THRD con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
THRD Third Harmonic Bio Inc	5.26	237.01M	0	-32.74M	-24.89M	-0.82
VRTX Vertex Pharmaceuticals Inc	461.68	118.90B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	672.98	73.95B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	655.13	39.81B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	271.31	34.99B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	123.77	29.67B	3.30B	-501.07M	1.03B	-2.1146

Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-08-09	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2024-06-18	Iniziato	Stifel	Buy
2024-06-07	Iniziato	Raymond James	Outperform
2022-12-16	Downgrade	Jefferies	Buy → Hold
2022-12-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-10-10	Iniziato	Cowen	Outperform
2022-10-10	Iniziato	Jefferies	Buy
2022-10-10	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Third Harmonic Bio Inc Borsa (THRD) Ultime notizie

Feb 01, 2025

Soho House, Third Harmonic Bio, and More Stocks See Action From Activist Investors - MSN

Feb 01, 2025

Jan 28, 2025

Where are the Opportunities in (THRD) - Stock Traders Daily

Jan 28, 2025

Third Harmonic Bio stock hits 52-week low at $5.58 - MSN

Jan 28, 2025

Jan 23, 2025

Haoxi Health Technology announces 1-for-25 reverse share split; shares plummet - MSN

Jan 23, 2025

Jan 22, 2025

GENERAL ATLANTIC, L.P. Acquires Additional Shares in Third Harmo - GuruFocus.com

Jan 22, 2025

Jan 21, 2025

Sionna, Odyssey join queue of biotechs testing investors’ IPO interest - BioPharma Dive

Jan 21, 2025

Jan 18, 2025

Trend Tracker for (THRD) - Stock Traders Daily

Jan 18, 2025

Jan 17, 2025

Papaya Growth Opportunity Stock Hits All-Time High of $12.5 - MSN

Jan 17, 2025

Jan 14, 2025

Jefferies cuts Third Harmonic stock target to $7 from $15 By Investing.com - Investing.com Canada

Jan 14, 2025

Jan 13, 2025

Third Harmonic Bio shares drop to lowest since 2023 By Investing.com - Investing.com Canada

Jan 13, 2025

Jan 10, 2025

Third Harmonic Bio stock hits 52-week low at $8.04 - Investing.com India

Jan 10, 2025

Jan 09, 2025

Dermata Therapeutics Inc (DRMA): Major Improvements, Worth A Look - Stocks Register

Jan 09, 2025

Jan 08, 2025

Stifel maintains positive outlook on Celldex and Third Harmonic stocks By Investing.com - Investing.com Canada

Jan 08, 2025

Revance gains as it plans to enter talks with Teoxane on likely superior bid (RVNC:NASDAQ) - Seeking Alpha

Jan 08, 2025

Jan 07, 2025

Learn to Evaluate (THRD) using the Charts - Stock Traders Daily

Jan 07, 2025

Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews

Jan 07, 2025

Jan 06, 2025

Revance Therapeutics jumps after Teoxane offers $3.60 a share (NASDAQ:RVNC) - Seeking Alpha

Jan 06, 2025

Jan 03, 2025

Third Harmonic Bio's SWOT analysis: oral KIT inhibitor stock shows promise - Investing.com Australia

Dec 17, 2024

Dec 10, 2024

Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress - Investing.com India

Dec 10, 2024

Stock Market Analysis & Tools for Investors - Seeking Alpha

Dec 10, 2024

Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress By Investing.com - Investing.com South Africa

Dec 10, 2024

Dec 09, 2024

Dimension gets $500M to bankroll biotech’s convergence with tech - BioPharma Dive

Dec 09, 2024

Dec 05, 2024

Atlas Venture Announces $450 Million Fund XIV - Yahoo Finance

Dec 05, 2024

Nov 26, 2024

How the (THRD) price action is used to our Advantage - Stock Traders Daily

Nov 26, 2024

Nov 25, 2024

Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference - Marketscreener.com

Nov 25, 2024

Third Harmonic Bio to Present at Evercore HealthCONx Conference in December | THRD Stock News - StockTitan

Nov 25, 2024

Nov 20, 2024

Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade - MSN

Nov 20, 2024

Nov 19, 2024

Aclaris stock soars for second day on licensing deal, analyst upgrades (NASDAQ:ACRS) - Seeking Alpha

Nov 19, 2024

Nov 18, 2024

Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise (NASDAQ:AMLX) - Seeking Alpha

Nov 18, 2024

Nov 15, 2024

(THRD) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 15, 2024

RA Capital Management Reduces Stake in Third Harmonic Bio Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Significant Stake Increase by T. Rowe Price in Third Harmonic Bi - GuruFocus.com

Nov 14, 2024

Nov 12, 2024

Revance Therapeutics jumps after Crown Laboratories tender offer extended again - Seeking Alpha

Nov 12, 2024

Nov 11, 2024

Vertiv Rises 13% in a Month: Time for Investors to Buy the Stock? - MSN

Nov 11, 2024

Shiba Inu (SHIB) Price Rises 53% but Hits Rejection at Key Ascending Resistance Level - MSN

Nov 11, 2024

Nov 08, 2024

Canopy Growth stock on watch after Q2 results (CGC:NASDAQ) - Seeking Alpha

Nov 08, 2024

Third Harmonic Bio Reports Q3 2024 Financial Results - TipRanks

Nov 08, 2024

Nov 07, 2024